FDA awards six additional Commissioner’s National Priority Vouchers

The U.S. Food and Drug Administration has awarded six additional Commissioner’s National Priority Vouchers (CNPVs), continuing its push to accelerate review timelines for therapies tied to U.S public health priorities.

The latest recipients include treatments for:

• Zongertinib (Boehringer Ingelheim) for HER2 lung cancer
• Bedaquiline (Johnson & Johnson) for drug-resistant TB in young children
• Dostarlimab (GSK) for rectal cancer
• Casgevy (Vertex Pharmaceuticals) for sickle cell disease
• Orforglipron (Eli Lilly) for obesity and related health conditions
• Wegovy (Novo Nordisk) for obesity and related health conditions

Notably, both Eli Lilly and Novo Nordisk received vouchers for obesity therapies, highlighting the FDA’s recognition of obesity as a major U.S long-term health challenge.

‍

Source: Press Release